Halsa Pharmaceuticals, Inc. is a biotechnology company that is developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases. One key therapeutic in development is a prescription drug showing significant promise for the treatment of obesity, diabetes and other metabolic diseases, called ZAG (Zinc-Alpha-2-Glycoprotein), an injectable medicine that is intended to diminish body fat in individuals, helping them achieve a healthier body weight. The basis of the medicine is a patented biological material that occurs naturally in the human body and acts as a pivotal regulator of body fat. A second therapeutic is for the treatment of cancer cachexia, the profound loss of body mass that accompanies the disease. Halsaâs program in this area is taking advantage of a class of therapeutics that interfere with the biological pathways that generate cachexia, specifically the (PIFR) Proteolysis-Induction Factor Receptor
